|
 |
FondaparinuxThis page contains recent news articles, when available, and an overview of Fondaparinux but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Fondaparinux (when available) Fondaparinux is a synthetic and specific inhibitor of activated Factor X (Xa) indicated for the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism. Fondaparinux is also indicated for the treatment of acute deep vein thrombosis when administered in conjunction with warfarin, and the treatment of acute pulmonary embolism when administered in conjunction with warfarin. Fondaparinux does not inactivate thrombin (activated Factor II) and has no known effect on platelet function. At the recommended dose, Fondaparinux does not affect fibrinolytic activity or bleeding time. For the treatment of prophylaxis of deep vein thrombosis. Mechanism Of Action: The antithrombotic activity of Fondaparinux is the result of antithrombin III (ATIII)-mediated selective inhibition of Factor Xa. By selectively binding to ATIII, Fondaparinux potentiates (about 300 times) the innate neutralization of Factor Xa by ATIII. Neutralization of Factor Xa interrupts the blood coagulation cascade and thus inhibits thrombin formation and thrombus development. News Articles on Fondaparinux Preliminary Final Report - Aug 21, 2008 This is mainly due to the assumption of fondaparinux manufacturing costs by Dr Reddys (DRLL). At 30 June 2008, the balance sheet includes a receivable of Sydney Morning Herald, Pre-Hospital Treatment On The Way To Percutaneous Coronary ... - Sep 2, 2008 ...(Fondaparinux, a factor Xa inhibitor, has been compared with heparin or placebo in 12092 STEMI patients treated with fibrinolytic agents or primary PCI or Medical News Today (press release), Changing Trends in Anti-Coagulant Therapies. Are Heparins and Oral ... - Aug 22, 2008 The synthetic pentasaccharide (Fondaparinux) has undergone clinical development. Unexpectedly, Fondaparinux also produced major bleeding problems at minimal RedOrbit, Deep Vein Thrombosis—Concepts and Controversy - Aug 25, 2008 5 The ACCP panel concluded that patients undergoing elective THA or TKA should receive either LMWH (grade 1A), fondaparinux (grade 1A), or a vitamin K Ortho SuperSite, Managing Risk of Bleeding in Patients Prior to Antithrombotic ... - Sep 5, 2008 In this context, some anticoagulants such as fondaparinux and bivalirudin have been shown to carry a lower risk of bleeding compared with low molecular DG News Safety of antithrombotic treatment in acute coronary syndromes - Sep 2, 2008 In this context, some anticoagulants have been shown to carry a lower risk of bleeding, such as fondaparinux and bivalirudin, as compared to low molecular EurekAlert (press release), What's New in Total Hip Arthroplasty - Sep 1, 2008 The anticoagulants included warfarin (50%), aspirin (23.8%), low-molecular-weight heparin (13.4%), and fondaparinux (12.8%). No hematomas were recorded. Journal of Bone and Joint Surgery (subscription) ACCP releases updated guidelines on thromboembolic disease - Aug 4, 2008 The ACCP recommended initial treatment with low–molecular-weight heparin, unfractionated heparin or fondaparinux for at least five days in patients with HemOncToday, Koagulologia - postępy 2007 - Jul 28, 2008 Schindewolf B., Luxembourg B., Lindhoff-Last E.: Use of fondaparinux in patients with heparin-induced thrombocytopenia type II. J. Thromb. Medycyna Praktyczna, Nuove linee guida americane per l'infarto - Jul 12, 2008 ...con trombolisi si raccomanda un aunticoagulante per almeno 48 ore (eparina non frazionata, eparina a basso peso molecolare, bivaluridina, fondaparinux). Pillole.org, Successful management of acute thromboembolic disease complicated ... - 03 Jul 2008 We present two cases with massive pulmonary embolism and HIT, successfully treated with the administration of fondaparinux, an alternative anticoagulant, 7thSpace Interactive (press release), Alchemia wins patents for generic fondaparinux - Jun 25, 2008 Alchemia and its manufacturing partner Dr Reddy's have made progress towards commercialization of fondaparinux, with approval and launch expected in the Pharmaceutical Business Review Alchemia wins patents for generic fondaparinux - Jun 24, 2008 Alchemia (ASX: ACL) has been granted patents for two of its family of the synthetic heparin oligosaccharides used in its fondaparinux synthesis production Australian Life Scientist, Alchemia Still A Buy Despite Delays - Jun 22, 2008 The company's main product is a synthetic heparin known as fondaparinux that has been given approval for a launch in the first half of 2009, FN Arena News, 1 in 5 patients receive treatment to prevent life-threatening ... - Jun 2, 2008 Prescription drugs to prevent blood clots include warfarin, heparin and fondaparinux. "Expert consensus guidelines recommend that patients receive HULIQ (press release), Fewer than 1 in 5 patients receive treatment to prevent life ... - 02 Jun 2008 Prescription drugs to prevent blood clots include warfarin, heparin and fondaparinux. "Expert consensus guidelines recommend that patients receive EurekAlert (press release), Discrepancies in US/European guidelines on antithrombotics for ACS - May 8, 2008 They say that discrepancies on recommendations regarding enoxaparin and fondaparinux between US and European guidelines undermines confidence in the TheHeart.Org, Steve Flecknoe-Brown on heparin guidleines - May 19, 2008 Fondaparinux is a synthetic heparinoid which is proven to be safe and effective. It is superior to enoxaparin for thromboprophylaxis in association with hip 6minutes, Parenteral anticoagulation may prolong the survival of patients ... - May 15, 2008 Results: Of 3986 identified citations, we included 5 RCTs, none of which evaluated fondaparinux. The quality of evidence was high for survival, 7thSpace Interactive (press release), Multimodal Thromboprophylaxis Following Primary Hip Arthroplasty - May 21, 2008 There is some evidence that in patients receiving fondaparinux the addition of compression stockings does not add significant protection.23 Number of RedOrbit, A balanced approach to risk/benefits of thromboembolic prophylaxis ... - May 6, 2008 Overall, patients who receive warfarin as primary prophylaxis may have a slighter higher DVT rate; however LMWH and fondaparinux sodium (Arixtra, Ortho SuperSite, Fondaparinux in Patients with Impaired Renal Function: The Right ... - Mar 31, 2008 To optimize both safety and efficacy, we chose the dose of fondaparinux on the basis of the PENTUA (Pentasaccharide in Unstable Angina) trial, Annals of Internal Medicine Anticoagulants May Increase Mortality After Hip and Knee Surgery - Apr 2, 2008 ...the risk was most pronounced with so-called potent anticoagulants, such as low-molecular weight heparin, ximelagatran, fondaparinux, and rivaroxaban. Therapeutics Daily (subscription) (press release), Systemic review finds that potent anticoagulants increase the risk ... - Apr 1, 2008 Specifically, Group A included the use of low-molecular-weight heparin, ximelagatran, fondaparinux or rivaroxaban, Group B included the use of a multimodal Ortho SuperSite, AAOS: Aspirin Prevents VTE in Real World Use After Knee Surgery - Mar 6, 2008 Aspirin use was associated with a risk of deep vein thrombosis or pulmonary embolism that matched low-molecular-weight heparin or fondaparinux (Arixtra) and MedPage Today, Aspirin Safe for Emboli Prevention After Knee Replacement in ... - Mar 7, 2008 ...treated with aspirin; 51923 patients treated with adjusted-dose warfarin; and 37198 patients treated with low-molecular-weight heparin or fondaparinux. DG News Montagner Named To Alchemia Board - Mar 7, 2008 The company's lead program is fondaparinux, which was recently partnered with Dr Reddy's Laboratories Inc. for the US market. Trading Markets (press release), Alchemia Announces Appointment of Non Executive Director - Mar 7, 2008 The Company's lead program is fondaparinux (synthetic heparin, a generic version of GlaxoSmithKline's Arixtra(R)) which is expected to generate near term Centre Daily Times, Transcript of Interview with Alchemia`s CEO - Feb 14, 2008 Its lead program is the commercialisation of a generic version of the synthetic heparin drug Arixtra, called fondaparinux. Alchemia's fondaparinux willl be Sydney Morning Herald, Alchemia Approaching Several Key Milestones in 2008 - Feb 26, 2008 Generic fondaparinux remains on track for approval around the end of calendar year ("CY") 2008, subject to review times at the US Food and Drug Business Wire (press release), Alchemia Appendix 4D - Feb 24, 2008 This is mainly due to the assumption of fondaparinux manufacturing costs by Dr Reddys. Matters subsequent to the half yearly financial period Except for the Sydney Morning Herald, Patients At Risk for VTE Not Receiving Prophylaxis - Feb 1, 2008 When dosing low-molecular-weight heparin (LMWH), fondaparinux, direct thrombin inhibitors, and other antithrombotic drugs that are cleared by the kidneys, Insider Medicine, Venous Thromboembolism and the Archives of Internal Medicine, 1908 ... - Jan 14, 2008 In 2002, Turpie et al 10 reported the results of 4 randomized clinical trials comparing fondaparinux, a selective factor Xa inhibitor, with enoxaparin in Archives of Internal Medicine Alchemia Announces Successful Pre-IND Meeting With the US FDA - Feb 1, 2008 The Company's lead program is fondaparinux (synthetic heparin, a generic version of GlaxoSmithKline's Arixtra(R)) which is expected to generate near term PR-Inside.com (Pressemitteilung), OASIS-5: PCI results published - Oct 22, 2007 Hamilton, ON - Results from an analysis of patients undergoing PCI in the OASIS-5 study comparing fondaparinux (Arixtra, glaxosmithkline) and enoxaparin TheHeart.Org, Antithrombotic Safety Linked to GFR - Oct 19, 2007 FONDAPARINUX may be safer than enoxaparin as treatment for non-ST-segment elevation acute coronary syndromes (ACS) in patients with renal dysfunction. Renal and Urology News, ASCO Issues Guidelines for Preventing and Treating Venous ... - Nov 6, 2007 Low-dose UFH, LMWH, or fondaparinux is recommended for patients undergoing laparotomy, laparoscopy, or thoracotomy lasting more than 30 minutes. Medscape (subscription) GSK Pharma net down 13% at Rs 249cr - Oct 25, 2007 In addition to the launch of Arixtra (Fondaparinux), a new generation blood thinning drug in the second quarter of this year, GSK had launched Carzec Business Standard, Aspirin: An appropriate prophylaxis for DVT - Nov 2, 2007 For instance, CMS advocates for low molecular weight heparin (LMWH), fondaparinux and warfarin, at an International Normalized Ratio (INR) between 2 and 3. Ortho SuperSite, DVT prophylaxis: What is your treatment choice? - Nov 2, 2007 ...regimes at the highest level for efficacy and safety: the two approved lmwhs, enoxaparin and dalteparin, fondaparinux and appropriately dosed warfarin. Ortho SuperSite, Is bivalirudin now the antithrombotic of choice in primary PCI? - Nov 1, 2007 Dr Shamir Mehta (mcmaster University, Hamilton, ON), who has been conducting studies with the competitor antithrombotic, fondaparinux (Arixtra, TheHeart.Org, Intensifying Platelet Inhibition — Navigating between Scylla and ... - Nov 4, 2007 Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006;354:1464-1476. [Free Full Text] Stone GW, mclaurin BT, Cox DA, New England Journal of Medicine (subscription), OASIS-5 substudy: Enoxaparin bleeding rates worse in renal ... - Sep 20, 2007 Edinburgh, Scotland - The benefits of fondaparinux over enoxaparin when administered for non-ST-segment elevation ACS are most marked among patients with TheHeart.Org, Influence of Renal Function on the Efficacy and Safety of ... - Sep 4, 2007 Objective: To compare the efficacy and safety of fondaparinux and enoxaparin over the spectrum of renal dysfunction observed in the OASIS 5 trial. Annals of Internal Medicine GlaxoSmithKlines Arixtra receives European authorisation for the ... - Sep 3, 2007 ..."The mortality benefit with fondaparinux compared to enoxaparin and the European authorisation of fondaparinux may allow physicians to consider a new Prdomain Business Register (press release), GSK wins extra EU nod for Arixtra - Sep 4, 2007 The green light for Arixtra (fondaparinux) was based on a review of two large-scale, pivotal Phase III trials involving more than 32000 patients (OASIS 5 Pharma Times (subscription), OASIS-5 substudy: Women fare worse with invasive strategy - Sep 3, 2007 OASIS-5 randomized 20 078 non-ST-elevation ACS patients within 24 hours to fondaparinux (2.5 mg sc once daily) or enoxaparin (1 mg/kg twice daily) for two TheHeart.Org, EMEA OKs Arixtra for UA/STEMI and STEMI - Sep 4, 2007 ...has approved the 2.5mg formulation of its once-daily anticoagulant Arixtra (fondaparinux sodium) for the treatment of certain acute coronary syndromes. Therapeutics Daily (subscription) (press release), ESC: Caution for Women on Early Invasive Treatment of Non-ST ... - Sep 5, 2007 The data she reported emerged from a sub-study of the OASIS-5 trial that compared fondaparinux (Arixtra) with enoxaparin (Lovenox) for treatment of non-ST MedPage Today, ACC/AHA Update Guidelines for Unstable Angina, NSTEMI - Aug 14, 2007 As expected, bivalirudin and fondaparinux have made it into the 2007 update. Both agents have a class 1 indication for use on top of antiplatelet therapy Medscape (subscription) Hospitals urged to treat blood clots - Aug 25, 2007 Traditional therapy to reduce the risk of blood clots includes blood-thinning drugs, such as heparin or fondaparinux, or compression stockings or shoes that Bradenton Herald, Celsus First to Manufacture Commercial Quantities of a generic ... - Aug 8, 2007 Venous thromboses is commonly treated with heparin sodium, or the low molecular weight heparins (LMWHs), or a synthetic alternative known as fondaparinux. PharmaLive.com (press release), GlaxoSmithKline's Arixtra® (fondaparinux Sodium) Receives Positive ... - Jul 8, 2007 Medical News Today (press release),..."We are delighted that the CHMP has given a positive opinion for fondaparinux in the setting of acute coronary syndrome," says Dr. Lawson Macartney, Alchemia Raises $15.2 Million With US and Australian Institutional ... - Jul 19, 2007 PharmaLive.com (press release),With fondaparinux (synthetic heparin) on track to generate near-term revenue, this financing enables accelerated clinical and commercial development for the Hospital patients at risk for clots - Aug 2, 2007 Baltimore Sun,Traditional therapy to reduce the risk of blood clots includes blood-thinning drugs, such as heparin or fondaparinux, or compression stockings or shoes that Discharged Hospital Patients Run Risk of Blood Clots - Jul 23, 2007 Forbes,One study compared the blood-thinning drug fondaparinux sodium with a placebo. "Although these agents reduce thrombotic events, they do not reduce all-cause Blood Clots Outside Hospital Could Be Prevented In Hospital - Jul 24, 2007 Medical News Today,Fondaparinux was shown to be effective in preventing venous thromboembolism. When compared with each other, low-molecular-weight heparin was associated with Enoxaparin Dosing in ACS Often Varies From Labeling, Can Raise ... - Jul 28, 2007 Medscape (subscription)However, this medication carries at least the same risk of major bleeding as unfractionated heparin or fondaparinux. The rate of major bleeding associated Apixaban Shows Efficacy as Monotherapy for Acute Symptomatic Deep ... - Jul 9, 2007 DG News...molecular weight heparin or fondaparinux followed by open-label vitamin K antagonist dose adjusted to an International Normalised Ratio of 2.0 to 3.0. GlaxoSmithKline's Arixtra(R) (fondaparinux sodium) receives ... - Jun 28, 2007 PipelineReview.com (press release),...“We are delighted that the CHMP has given a positive opinion for fondaparinux in the setting of acute coronary syndrome,� says Dr. Lawson Macartney, New Marketing and Manufacturing Partner Appointed for Synthetic ... - Apr 25, 2007 PR Newswire (press release),About Synthetic Heparin (Fondaparinux). Alchemia has used its proprietary carbohydrate technology to develop a generic version of the antithrombotic drug New Marketing and Manufacturing Partner Appointed for Synthetic ... - 26 Apr 2007 PR Newswire (press release),About Synthetic Heparin (Fondaparinux). Alchemia has used its proprietary carbohydrate technology to develop a generic version of the antithrombotic drug GlaxoSmithKline Receives Japanese Approval For Two Major New ... - Apr 23, 2007 Medical News Today (press release),Diskus (salmeterol and fluticasone proprionate combination) and Arixtra (fondaparinux sodium) from the Ministry of Health, Labour and Welfare in Japan. Japanese nod for GSK's Seretide/Advair and Arixtra - Apr 19, 2007 Pharma Times (subscription),GSK's anti-thrombotic Arixtra (fondaparinux sodium) has been cleared as a once-daily subcutaneous injection of 1.5mg and 2.5mg for the prevention of venous Fondaparinux significantly reduces risk of death for myocardial ... - Dec 19, 2006 Xagena.it,The study included 12092 patients with STEMI from 447 hospitals in 41 countries who were randomized to receive Fondaparinux 2.5 mg once daily for up to 8 Fondaparinux significantly reduces risk of death for myocardial ... - Dec 19, 2006 Xagena.it,The study included 12092 patients with STEMI from 447 hospitals in 41 countries who were randomized to receive Fondaparinux 2.5 mg once daily for up to 8 Brand Names/Synonyms: Fondaparinux is also known by the following brand names and/or synonymsArixtra; Fondaparinux sodium Drug Category: Fondaparinux is categorized under the following by the FDA: Anticoagulants; Antithrombotics; ATC:B01AX05 Dosage Forms: Solution Absorption: 100% Interactions: Interactions for Fondaparinux: In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium. In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin, acetylsalicylic acid, piroxicam, and digoxin, nor the pharmacokinetics of digoxin at steady state. Agents that may enhance the risk of hemorrhage should be discontinued prior to initiation of Fondaparinux therapy. If co-administration is essential, close monitoring may be appropriate. In an in vitro study in human liver microsomes, inhibition of CYP2A6 hydroxylation of coumarin by fondaparinux (200 m m M i.e., 350 mg/L) was 17-28%. Inhibition of the other isozymes evaluated (CYPs 2A1, 2C9, 2C19, 2D6, 3A4, and 3E1) was 0-16%. Since fondaparinux does not markedly inhibit CYP450s (CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4) in vitro, fondaparinux sodium is not expected to significantly interact with other drugs in vivo by inhibition of metabolism mediated by these isozymes. Since fondaparinux sodium does not bind significantly to plasma proteins other than ATIII, no drug interactions by protein-binding displacement are expected. Chemical IUPAC Name: decasodium 6-[6-[2-carboxylato-4-hydroxy-6-[4-hydroxy-6-methoxy-5-sulfonatoamino-2-(sulfonatooxymethyl)oxan-3-yl]oxy-5-sulfonatooxy-oxan-3-yl]oxy-5-sulfonatoamino-4-sulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxy-3-[4,5-dihydroxy-3-sulfonatoamino-6-(sulfonatooxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-oxane-2-carboxylate : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |